Business Context and Reporting Period
Company: Incyte Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 1999
Business Overview: Incyte designs, develops, and markets genomic information-based tools, including database products, software, microarray-based gene expression services, and genomic reagents. The company operates primarily in one segment and relies heavily on database collaboration agreements with pharmaceutical and biotechnology companies.
Key Financial Metrics
| Metric (in thousands) | Q1 1999 | Q1 1998 |
|---|---|---|
| Revenues | $37,630 | $30,379 |
| Net Income (Loss) | $(1,910) | $3,566 |
| Operating Income (Loss) | $(1,993) | $2,909 |
| Research & Development Expenses | $31,244 | $21,699 |
| Selling, General & Admin Expenses | $8,379 | $4,600 |
| Cash and Cash Equivalents (End of Period) | $83,546 | $42,726 |
| Total Cash, Equivalents & Marketable Securities | $133,730 | $N/A (Combined) |
| Net Cash Provided by Operating Activities | $31,662 | $31,943 |
| Accumulated Deficit | $(30,311) | $(28,401) |
Per Share Data: Basic and Diluted Net Loss per share was $(0.07) for Q1 1999, compared to Net Income per share of $0.13 (Basic) and $0.12 (Diluted) for Q1 1998.
Material Changes vs. Prior Period
- Profitability Reversal: The company reported a net loss of $1.9 million in Q1 1999, a significant shift from the $3.6 million net income reported in Q1 1998. This was driven by a $9.5 million increase in total costs and expenses.
- Revenue Growth: Revenues increased by approximately 24% to $37.6 million, attributed to new and expanded database collaboration agreements and increased activity in contract sequencing and microarray services.
- Expense Increases:
- R&D: Increased by $9.5 million (44%) due to expanded bioinformatics, genomic sequencing, gene mapping, SNP discovery efforts, and microarray production. Includes $0.6 million in goodwill amortization from the Hexagen acquisition.
- SG&A: Increased by $3.8 million (80%) due to UK operations expansion, sales/marketing growth, and approximately $2.1 million in legal expenses related to patent litigation.
- Liquidity: Cash and cash equivalents increased by $33.5 million to $83.5 million, despite capital expenditures of $8.9 million. Total liquid assets (cash, equivalents, and marketable securities) stood at $133.7 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Future Losses Expected: Management expects to report a net loss for the full year 1999 due to significant investments in genomic sequencing, mapping, and SNP discovery programs.
- Profitability Timeline: The company projects a return to profitability in the second half of 2000, contingent on the successful and timely completion of current R&D programs.
- Cash Flow: While cash flow from operations is expected to remain positive in 1999, a significant decrease is anticipated for the remainder of the year compared to 1998 due to heavy R&D investment.
- Capital Needs: Management believes existing resources and anticipated cash flows are adequate to satisfy capital needs for at least the next twelve months.
Material Risks and Contingencies
- Patent Litigation: Incyte and its subsidiary Synteni are defendants in two lawsuits filed by Affymetrix, Inc., alleging willful infringement of three patents related to high-density arrays and microarray technology. Affymetrix seeks permanent injunctions, damages, and treble damages. A preliminary injunction was denied in April 1999, with trial scheduled for July 2000. The company cannot estimate potential losses but expects substantial legal expenses.
- Acquisition Integration: Risks associated with integrating Hexagen Limited (acquired Sept 1998) and Synteni, Inc. (acquired Jan 1998), including potential impairment of goodwill and intangible assets.
- Joint Venture Losses: The company recorded a $1.4 million loss from its 50% interest in diaDexus, LLC, a joint venture with SmithKline Beecham. diaDexus is expected to incur operating losses through at least 2000.
- Year 2000 Compliance: Estimated costs to address Year 2000 issues range from $1.0 million to $1.5 million. Risks include potential disruptions from third-party vendors or customers failing to achieve compliance.
Investor Verification Checklist
- Litigation Status: Verify the current status of the Affymetrix patent infringement lawsuits and any potential settlement discussions or court rulings.
- R&D Milestones: Confirm progress on the genomic sequencing, mapping, and SNP discovery programs to assess the validity of the projected 2000 return to profitability.
- Deferred Revenue: Review the $53.1 million in deferred revenue on the balance sheet to understand the timing of future revenue recognition from database agreements.
- Joint Venture Viability: Assess the financial health and strategic value of the diaDexus joint venture given its continued operating losses.
- Capital Expenditures: Monitor capital spending levels to ensure they align with the company's stated investment plans for sequencing and microarray capacity.